RALEIGH, N.C., Nov. 16, 2015 (GLOBE NEWSWIRE) — PRA Health Sciences (PRA) (NASDAQ:PRAH) is pleased to announce that it is relocating to a new office in Singapore to support its expanded operations in the region. The move will allow PRA to consolidate its workforce and be strategically located near many of its clients in the area. The new office location is 21 Biopolis Road, Nucleos, Singapore.
“We are excited about this new location,” said Jonathan Newton, PRA Regional Senior Director, Clinical Operations (Asia Pac). “Singapore is an excellent center for clinical research and is the regional hub for PRA in Asia Pacific. This move is recognition of PRA’s commitment to meeting the growing needs of our clients and providing high-quality services in the region.”
Since 2000, PRA has been strategically expanding its Asia Pacific capabilities. In the past two years the Singapore workforce has doubled in size. Since 2010, PRA has conducted 23 clinical trials in Singapore and 3 non-clinical consulting projects.
“We are delighted that PRA values Singapore as a strategic location to coordinate operations in the region, and welcome their decision to invest further here. Their expansion helps to reinforce Singapore’s position as an excellent hub for companies to manage clinical trials across the Asia Pacific region, and as a clinical research location for early phase studies,” said Mr. Kevin Lai, Executive Director, Biomedical Sciences and Consumer Businesses, Singapore Economic Development Board (EDB).
As the Secretariat for the APEC Coordinating Centre for Good Clinical Practice (GCP), Singapore plays a strategic role in developing GCP in Asia, steering initiatives such as the training of clinical research personnel and developing a conducive environment for multi-site clinical trials in the region.
In 2015, PRA was named the Best Clinical Research Organization in Asia by BioPharma Asia Industry Awards. PRA also received this recognition in 2013.
ABOUT PRA HEALTH SCIENCES
At PRA Health Sciences, providing innovative solutions for our clients is what we do. Side-by-side with our clients, we strive to move drug discovery forward, helping them to develop life-saving and life-improving drugs. PRA has more than 11,000 employees working in 80+ countries providing comprehensive clinical development services across all phases. From full service clinical development to the pioneering Embedded Solutions™ model, PRA provides a broad spectrum of solutions that meet the demands of a diverse marketplace. PRA has worked on 100+ marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to FDA and/or international regulatory approval of 50+ such drugs.
MEDIA INQUIRIES: Christine Rogers, email@example.com, +1 919.786.8463 INVESTOR INQUIRIES: InvestorRelations@prahs.com
Copyright © 2015 GlobeNewswire, Inc.